Targeting ferroptosis resistance resensitizes metastatic HR+HER2− breast cancer cells to palbociclib‐hormone therapy

Targeting ferroptosis resistance resensitizes metastatic HR+HER2− breast cancer cells to palbociclib‐hormone therapy

Saved in:

Bibliographic Details
Main Authors:	Charles Pottier, Laetitia Montero‐Ruiz, Robin Jehay, Coline Wery, Dominique Baiwir, Gabriel Mazzucchelli, Sophie Bekisz, Romain Thissen, Claire Josse, Andrée Rorive, Stéphanie Gofflot, Ahmed Dahmani, Ludivine Morisset, Joëlle Collignon, Philipe Delvenne, Elisabetta Marangoni, Agnès Noël, Guy Jerusalem, Nor Eddine Sounni
Format:	Article
Language:	English
Published:	Wiley 2025-04-01
Series:	Cancer Communications
Online Access:	https://doi.org/10.1002/cac2.12646
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bacteriophage Indie resensitizes multidrug-resistant Acinetobacter baumannii to antibiotics in vitro
by: Alma Karen Orozco-Ochoa, et al.
Published: (2025-04-01)

Vitamin B6 resensitizes mcr-carrying Gram-negative bacteria to colistin
by: Tianqi Xu, et al.
Published: (2025-03-01)

Palbociclib as an Antitumor Drug: A License to Kill
by: Agnieszka Łupicka-Słowik, et al.
Published: (2024-11-01)

Neutropenia due to palbociclib: A word of caution?
by: Raja Pramanik, et al.
Published: (2016-01-01)

Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial
by: Jacob J. Orme, et al.
Published: (2025-03-01)

Resensitizing β‐Lactams by Reprogramming Purine Metabolism in Small Colony Variant for Osteomyelitis Treatment
by: Tingwang Shi, et al.
Published: (2025-02-01)

Harnessing CRISPR interference to resensitize laboratory strains and clinical isolates to last resort antibiotics
by: Angelica Frusteri Chiacchiera, et al.
Published: (2025-01-01)

Non‐Membrane Active Peptide Resensitizes MRSA to β‐Lactam Antibiotics and Inhibits S. aureus Virulence
by: Jingru Shi, et al.
Published: (2025-04-01)

Chemoresistance is associated with overexpression of HAX-1, inhibition of which resensitizes drug-resistant breast cancer cells to chemotherapy
by: Ji Yang, et al.
Published: (2017-03-01)

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
by: Jenna L. Carter, et al.
Published: (2025-01-01)

Microdynamic flowability for early API characterisation: A case study on Palbociclib
by: David Blanco, et al.
Published: (2025-12-01)

Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai
by: Vijay Gnanaguru, et al.
Published: (2020-01-01)

Genome-wide antibiotic-CRISPRi profiling identifies LiaR activation as a strategy to resensitize fluoroquinolone-resistant Streptococcus pneumoniae
by: Bevika Sewgoolam, et al.
Published: (2025-07-01)

Enhancing palbociclib efficacy with low toxicity in breast cancer using polycaprolactone-based nanocarriers
by: Nastaran Zerang, et al.
Published: (2025-05-01)

Surface functionalized albumin nanoparticles of palbociclib with amplified brain delivery for treating brain glioblastoma
by: Vishwanath Kurawattimath, et al.
Published: (2025-08-01)

Inhibition of platin-induced BCL2 increase overcomes chemoresistance in squamous cell carcinoma of the head and neck through resensitization to cell death
by: Anne-Sophie Becker, et al.
Published: (2025-03-01)

CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER
by: E. N. Imyanitov, et al.
Published: (2017-12-01)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
by: Eric Raspé, et al.
Published: (2017-05-01)

Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom
by: Gaurav Suri, et al.
Published: (2019-04-01)

Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial
by: Joan Albanell, et al.
Published: (2025-06-01)

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities
by: Mashael Algethami, et al.
Published: (2025-08-01)

Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
by: Emilie Adrian Christiansen, et al.
Published: (2024-12-01)

Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors
by: John C. Panetta, et al.
Published: (2024-11-01)

Small Molecules from Medicinal Plant <i>Iris tectorum</i> as Histidine Kinase Inhibitor to Resensitize β-Lactam-Resistant <i>Escherichia coli</i>
by: Youqi Ji, et al.
Published: (2025-02-01)

CD4+ lymphocytopenia and Pneumocystis jirovecii pneumonia in a metastatic breast cancer patient treated with palbociclib and corticosteroids
by: Shahar Dekel, et al.
Published: (2025-07-01)

Cisplatin palbociclib combination differentially modulates PTEN AKT signaling via Hsp90 in hepatocellular carcinoma cells
by: Hameis M. Sleem, et al.
Published: (2025-06-01)

Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2− MBC patients living in disadvantaged neighborhoods
by: Filipa Lynce, et al.
Published: (2025-07-01)

Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer
by: Stanley Madu Nwabudike, et al.
Published: (2018-01-01)

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
by: Sonia Pernas, et al.
Published: (2024-11-01)

Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
by: Victoria Roulstone, et al.
Published: (2025-05-01)

PALBOCICLIB IN COMBINATION WITH HORMONE THERAPY FOR LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER: NEW HIGHLY EFFECTIVE STRATEGY OF DRUG TREATMENT
by: E. V. Artamonova
Published: (2017-09-01)

TMEM45A enhances palbociclib resistance and cellular glycolysis by activating AKT/mTOR signaling pathway in HR+ breast cancer
by: Cui Chen, et al.
Published: (2025-02-01)

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer
by: Adam M. Brufsky, et al.
Published: (2025-04-01)

Neología semántica y polisemia: el caso del truncamiento
by: Marie Steffens, et al.
Published: (2009-12-01)

Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
by: Victoria Roulstone, et al.
Published: (2025-07-01)

Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2− Metastatic Breast Cancer
by: Pluard TJ, et al.
Published: (2025-03-01)

Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center
by: Sandeep K. S, et al.
Published: (2025-04-01)

Palbociclib-induced Toxic Epidermal Necrolysis: A Case Report with Review of All Cases Secondary to Cyclin-dependent Kinase 4/6 Inhibitors
by: Aurore Devoldere, et al.
Published: (2025-01-01)

Escaudain (Nord). Rue des Semailles
by: Maël Julien, et al.
Published: (2012-12-01)

Quiéry-la-Motte (Pas-de-Calais). « Le Marquaille », Chemin de Beaumont
by: Étienne Louis, et al.
Published: (2011-12-01)